TY - JOUR AU - Jiang, X. J. AU - Huang, K. K. AU - Yang, M. AU - Qiao, L. AU - Wang, Q. AU - Ye, J. Y. PY - 2012 DA - 2012// TI - Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways JO - Cancer Lett. VL - 326 UR - https://doi.org/10.1016/j.canlet.2012.07.030 DO - 10.1016/j.canlet.2012.07.030 ID - Jiang2012 ER - TY - JOUR AU - Tallman, M. S. AU - Gilliland, D. G. AU - Rowe, J. M. PY - 2015 DA - 2015// TI - Drug therapy for acute myeloid leukemia JO - Blood VL - 106 UR - https://doi.org/10.1182/blood-2005-01-0178 DO - 10.1182/blood-2005-01-0178 ID - Tallman2015 ER - TY - JOUR AU - McCubrey, J. A. AU - Steelman, L. S. AU - Franklin, R. A. AU - Abrams, S. L. AU - Chappell, W. H. AU - Wong, E. W. PY - 2007 DA - 2007// TI - Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance JO - Adv Enzyme Regul. VL - 47 UR - https://doi.org/10.1016/j.advenzreg.2006.12.013 DO - 10.1016/j.advenzreg.2006.12.013 ID - McCubrey2007 ER - TY - JOUR AU - Panwalkar, A. AU - Verstovsek, S. AU - Giles, F. PY - 2004 DA - 2004// TI - Nuclear factor-KappaB modulation as a therapeutic approach in hematologic malignancies JO - Cancer VL - 100 UR - https://doi.org/10.1002/cncr.20182 DO - 10.1002/cncr.20182 ID - Panwalkar2004 ER - TY - JOUR AU - Cai, S. F. AU - Levine, R. L. PY - 2019 DA - 2019// TI - Genetic and epigenetic determinants of AML pathogenesis JO - Semin Hematol. VL - 56 UR - https://doi.org/10.1053/j.seminhematol.2018.08.001 DO - 10.1053/j.seminhematol.2018.08.001 ID - Cai2019 ER - TY - JOUR AU - Jiang, X. AU - Wang, Z. AU - Ding, B. AU - Yin, C. AU - Zhong, Q. AU - Carter, B. Z. PY - 2015 DA - 2015// TI - The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients JO - Oncotarget. VL - 6 UR - https://doi.org/10.18632/oncotarget.5600 DO - 10.18632/oncotarget.5600 ID - Jiang2015 ER - TY - JOUR AU - Vishwakarma, B. A. AU - Nguyen, N. AU - Makishima, H. AU - Hosono, N. AU - Gudmundsson, K. O. AU - Negi, V. PY - 2016 DA - 2016// TI - Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development JO - Leukemia VL - 30 UR - https://doi.org/10.1038/leu.2015.200 DO - 10.1038/leu.2015.200 ID - Vishwakarma2016 ER - TY - JOUR AU - Wouters, B. J. AU - Delwel, R. PY - 2016 DA - 2016// TI - Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2015-07-604512 DO - 10.1182/blood-2015-07-604512 ID - Wouters2016 ER - TY - JOUR AU - Catley, L. AU - Weisberg, E. AU - Kiziltepe, T. AU - Tai, Y. T. AU - Hideshima, T. AU - Neri, P. PY - 2006 DA - 2006// TI - Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells JO - Blood VL - 108 UR - https://doi.org/10.1182/blood-2006-04-016055 DO - 10.1182/blood-2006-04-016055 ID - Catley2006 ER - TY - JOUR AU - Gregoretti, I. V. AU - Lee, Y. M. AU - Goodson, H. V. PY - 2004 DA - 2004// TI - Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis JO - J Mol Biol. VL - 338 UR - https://doi.org/10.1016/j.jmb.2004.02.006 DO - 10.1016/j.jmb.2004.02.006 ID - Gregoretti2004 ER - TY - JOUR AU - West, A. C. AU - Johnstone, R. W. PY - 2014 DA - 2014// TI - New and emerging HDAC inhibitors for cancer treatment JO - J Clin Invest. VL - 124 UR - https://doi.org/10.1172/JCI69738 DO - 10.1172/JCI69738 ID - West2014 ER - TY - JOUR AU - Martin-Perez, D. AU - Piris, M. A. AU - Sanchez-Beato, M. PY - 2010 DA - 2010// TI - Polycomb proteins in hematological malignancies JO - Blood VL - 116 UR - https://doi.org/10.1182/blood-2010-05-267096 DO - 10.1182/blood-2010-05-267096 ID - Martin-Perez2010 ER - TY - JOUR AU - Ungerstedt, J. S. PY - 2018 DA - 2018// TI - Epigenetic modifiers in myeloid malignancies: The Role of histone deacetylase inhibitors JO - Int J Mol Sci. VL - 19 UR - https://doi.org/10.3390/ijms19103091 DO - 10.3390/ijms19103091 ID - Ungerstedt2018 ER - TY - JOUR AU - San José-Enériz, E. AU - Gimenez-Camino, N. AU - Agirre, X. AU - Prosper, F. PY - 2019 DA - 2019// TI - HDAC inhibitors in acute myeloid leukemia JO - Cancers (Basel). VL - 11 UR - https://doi.org/10.3390/cancers11111794 DO - 10.3390/cancers11111794 ID - San José-Enériz2019 ER - TY - JOUR AU - Momparler, R. L. AU - Côté, S. AU - Momparler, L. F. AU - Idaghdour, Y. PY - 2014 DA - 2014// TI - Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation JO - Clin Epigenetics. VL - 6 UR - https://doi.org/10.1186/1868-7083-6-19 DO - 10.1186/1868-7083-6-19 ID - Momparler2014 ER - TY - JOUR AU - Gong, K. AU - Xie, J. AU - Yi, H. AU - Li, W. PY - 2012 DA - 2012// TI - CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells JO - Biochem J. VL - 443 UR - https://doi.org/10.1042/BJ20111685 DO - 10.1042/BJ20111685 ID - Gong2012 ER - TY - JOUR AU - Shi, Y. AU - Jia, B. AU - Xu, W. AU - Li, W. AU - Liu, T. AU - Liu, P. PY - 2017 DA - 2017// TI - Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China JO - J Hematol Oncol. VL - 10 UR - https://doi.org/10.1186/s13045-017-0439-6 DO - 10.1186/s13045-017-0439-6 ID - Shi2017 ER - TY - JOUR AU - Guan, W. AU - Jing, Y. AU - Dou, L. AU - Wang, M. AU - Xiao, Y. AU - Yu, L. PY - 2020 DA - 2020// TI - Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia JO - Leuk Lymphoma. VL - 61 UR - https://doi.org/10.1080/10428194.2019.1691195 DO - 10.1080/10428194.2019.1691195 ID - Guan2020 ER - TY - JOUR AU - Guan, X. W. AU - Wang, H. Q. AU - Ban, W. W. AU - Chang, Z. AU - Chen, H. Z. AU - Jia, L. PY - 2020 DA - 2020// TI - Novel HDAC inhibitor chidamide synergizes with rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20 JO - Cell Death Dis. VL - 11 UR - https://doi.org/10.1038/s41419-019-2210-0 DO - 10.1038/s41419-019-2210-0 ID - Guan2020 ER - TY - JOUR AU - Hu, X. AU - Wang, L. AU - Lin, L. AU - Han, X. AU - Dou, G. AU - Meng, Z. PY - 2016 DA - 2016// TI - A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer JO - Chin J Cancer Res. VL - 28 UR - https://doi.org/10.21147/j.issn.1000-9604 DO - 10.21147/j.issn.1000-9604 ID - Hu2016 ER - TY - JOUR AU - Zhao, S. AU - Guo, J. AU - Zhao, Y. AU - Fei, C. AU - Zheng, Q. AU - Li, X. PY - 2016 DA - 2016// TI - Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling JO - Am J Transl Res VL - 8 ID - Zhao2016 ER - TY - JOUR AU - Li, Y. AU - Chen, K. AU - Zhou, Y. AU - Xiao, Y. AU - Deng, M. AU - Jiang, Z. PY - 2015 DA - 2015// TI - A new strategy to target acute myeloid leukemia stem and progenitor cells using chidamide, a histone deacetylase inhibitor JO - Curr Cancer Drug Targets. VL - 15 UR - https://doi.org/10.2174/156800961506150805153230 DO - 10.2174/156800961506150805153230 ID - Li2015 ER - TY - JOUR AU - Li, Y. AU - Wang, Y. AU - Zhou, Y. AU - Li, J. AU - Chen, K. AU - Zhang, L. PY - 2017 DA - 2017// TI - Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells JO - Clin Epigenetics. VL - 9 UR - https://doi.org/10.1186/s13148-017-0377-8 DO - 10.1186/s13148-017-0377-8 ID - Li2017 ER - TY - JOUR AU - Huang, H. AU - Wenbing, Y. AU - Dong, A. AU - He, Z. AU - Yao, R. AU - Guo, W. PY - 2019 DA - 2019// TI - Chidamide enhances the cytotoxicity of cytarabine and sorafenib in acute myeloid leukemia cells by modulating H3K9me3 and autophagy levels JO - Front Oncol. VL - 9 UR - https://doi.org/10.3389/fonc.2019.01276 DO - 10.3389/fonc.2019.01276 ID - Huang2019 ER - TY - JOUR AU - Dedoni, S. AU - Marras, L. AU - Olianas, M. C. AU - Ingianni, A. AU - Onali, P. PY - 2019 DA - 2019// TI - Downregulation of TrkB expression and signaling by valproic acid and other histone deacetylase inhibitors JO - J Pharmacol Exp Ther. VL - 370 UR - https://doi.org/10.1124/jpet.119.258129 DO - 10.1124/jpet.119.258129 ID - Dedoni2019 ER - TY - JOUR AU - Shi, B. AU - Behrens, C. AU - Vaghani, V. AU - Riquelme, E. M. AU - Rodriguez-Canales, J. AU - Kadara, H. PY - 2019 DA - 2019// TI - Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer JO - Cancer Med. VL - 8 UR - https://doi.org/10.1002/cam4.1855 DO - 10.1002/cam4.1855 ID - Shi2019 ER - TY - JOUR AU - Stasik, S. AU - Middeke, J. M. AU - Kramer, M. AU - Röllig, C. AU - Krämer, A. AU - Scholl, S. PY - 2020 DA - 2020// TI - EZH2 mutations and impact on clinical outcome - an analysis in 1604 patients with newly diagnosed acute myeloid leukemia JO - Haematologica VL - 105 UR - https://doi.org/10.3324/haematol.2019.222323 DO - 10.3324/haematol.2019.222323 ID - Stasik2020 ER - TY - JOUR AU - Sauvageau, M. AU - Sauvageau, G. PY - 2010 DA - 2010// TI - Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer JO - Cell Stem Cell VL - 7 UR - https://doi.org/10.1016/j.stem.2010.08.002 DO - 10.1016/j.stem.2010.08.002 ID - Sauvageau2010 ER - TY - JOUR AU - Sasaki, D. AU - Imaizumi, Y. AU - Hasegawa, H. AU - Osaka, A. AU - Tsukasaki, K. AU - Choi, Y. L. PY - 2011 DA - 2011// TI - Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy JO - Haematologica VL - 96 UR - https://doi.org/10.3324/haematol.2010.028605 DO - 10.3324/haematol.2010.028605 ID - Sasaki2011 ER - TY - JOUR AU - Bachmann, I. M. AU - Halvorsen, O. J. AU - Collett, K. AU - Stefansson, I. M. AU - Straume, O. AU - Haukaas, S. A. PY - 2006 DA - 2006// TI - EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast JO - J Clin Oncol. VL - 24 UR - https://doi.org/10.1200/JCO.2005.01.5180 DO - 10.1200/JCO.2005.01.5180 ID - Bachmann2006 ER - TY - JOUR AU - Tanaka, S. AU - Miyagi, S. AU - Sashida, G. AU - Chiba, T. AU - Yuan, J. AU - Mochizuki-Kashio, M. PY - 2012 DA - 2012// TI - Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2011-11-394932 DO - 10.1182/blood-2011-11-394932 ID - Tanaka2012 ER - TY - JOUR AU - Fujita, S. AU - Honma, D. AU - Adachi, N. AU - Araki, K. AU - Takamatsu, E. AU - Katsumoto, T. PY - 2018 DA - 2018// TI - Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia JO - Leukemia VL - 32 UR - https://doi.org/10.1038/leu.2017.300 DO - 10.1038/leu.2017.300 ID - Fujita2018 ER - TY - JOUR AU - Singh, A. N. AU - Sharma, N. PY - 2019 DA - 2019// TI - Epigenetic modulators as potential multi-targeted drugs against hedgehog pathway for treatment of cancer JO - Protein J. VL - 38 UR - https://doi.org/10.1007/s10930-019-09832-9 DO - 10.1007/s10930-019-09832-9 ID - Singh2019 ER - TY - JOUR AU - Terao, T. AU - Minami, Y. PY - 2009 DA - 2009// TI - Targeting Hedgehog (Hh) pathway for the acute myeloid leukemia treatment JO - Cells VL - 8 UR - https://doi.org/10.3390/cells8040312 DO - 10.3390/cells8040312 ID - Terao2009 ER - TY - JOUR AU - Irvine, D. A. AU - Copland, M. PY - 2012 DA - 2012// TI - Targeting Hedgehog in hematologic malignancy JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-10-383752 DO - 10.1182/blood-2011-10-383752 ID - Irvine2012 ER - TY - JOUR AU - Wellbrock, J. AU - Latuske, E. AU - Köhler, J. AU - Wagner, K. AU - Stamm, H. AU - Vettorazzi, E. PY - 2015 DA - 2015// TI - Expression of Hedgehog pathway mediator GLI represents a negative prognostic marker in human acute myeloid leukemia and its inhibition exerts antileukemic effects JO - Clin Cancer Res. VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-1059 DO - 10.1158/1078-0432.CCR-14-1059 ID - Wellbrock2015 ER - TY - JOUR AU - Thomas, X. AU - Heiblig, M. PY - 2020 DA - 2020// TI - An evaluation of glasdegib for the treatment of acute myelogenous leukemia JO - Expert opin pharmacother. VL - 21 UR - https://doi.org/10.1080/14656566.2020.1713094 DO - 10.1080/14656566.2020.1713094 ID - Thomas2020 ER - TY - JOUR AU - Wolska-Washer, A. AU - Robak, T. PY - 2019 DA - 2019// TI - Glasdegib in the treatment of acute myeloid leukemia JO - Future Oncol. VL - 15 UR - https://doi.org/10.2217/fon-2019-0171 DO - 10.2217/fon-2019-0171 ID - Wolska-Washer2019 ER - TY - JOUR AU - Savona, M. R. AU - Pollyea, D. A. AU - Stock, W. AU - Oehler, V. G. AU - Schroeder, M. A. AU - Lancet, J. PY - 2018 DA - 2018// TI - Phase Ib study of glasdegib, a Hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS JO - Clin Cancer Res. VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-2824 DO - 10.1158/1078-0432.CCR-17-2824 ID - Savona2018 ER - TY - JOUR AU - Lima-Fernandes, E. AU - Murison, A. AU - Silva Medina, T. AU - Wang, Y. AU - Ma, A. AU - Leung, C. PY - 2019 DA - 2019// TI - Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells JO - Nat Commun. VL - 10 UR - https://doi.org/10.1038/s41467-019-09309-4 DO - 10.1038/s41467-019-09309-4 ID - Lima-Fernandes2019 ER - TY - JOUR AU - Zhu, Q. AU - Zhang, L. AU - Li, X. AU - Chen, F. AU - Jiang, L. AU - Yu, G. PY - 2016 DA - 2016// TI - Higher EZH2 expression is associated with extramedullary infiltration in acute myeloid leukemia JO - Tumour Biol. VL - 37 UR - https://doi.org/10.1007/s13277-016-4983-4 DO - 10.1007/s13277-016-4983-4 ID - Zhu2016 ER - TY - JOUR AU - Huang, K. AU - Sun, Z. AU - Ding, B. AU - Jiang, X. AU - Wang, Z. AU - Zhu, Y. PY - 2019 DA - 2019// TI - Suppressing Hedgehog signaling reverses drug resistance of refractory acute myeloid leukemia JO - Onco Targets Ther. VL - 12 UR - https://doi.org/10.2147/OTT.S216628 DO - 10.2147/OTT.S216628 ID - Huang2019 ER - TY - JOUR AU - Li, X. AU - Chen, F. AU - Zhu, Q. AU - Ding, B. AU - Zhong, Q. AU - Huang, K. PY - 2016 DA - 2016// TI - Gli-1/PI3K/AKT/NF-kB pathway mediates resistance to radiation and is a target for reversion of responses in refractory acute myeloid leukemia cells JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.8844 DO - 10.18632/oncotarget.8844 ID - Li2016 ER - TY - JOUR AU - Jiang, X. AU - Mak, P. Y. AU - Mu, H. AU - Tao, W. AU - Mak, D. AU - Kornblau, S. PY - 2018 DA - 2018// TI - Disruption of Wnt/β-catenin exerts antileukemia activity and synergizes with FLT3 inhibition in FLT3-mutant acute myeloid leukemia JO - Clin Cancer Res. VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-1556 DO - 10.1158/1078-0432.CCR-17-1556 ID - Jiang2018 ER - TY - JOUR AU - Jin, J. AU - Mao, S. AU - Li, F. AU - Li, X. AU - Huang, X. AU - Yu, M. PY - 2019 DA - 2019// TI - A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells JO - Med Oncol. VL - 36 UR - https://doi.org/10.1007/s12032-019-1302-0 DO - 10.1007/s12032-019-1302-0 ID - Jin2019 ER - TY - STD TI - Tu HJ, Lin YJ, Chao MW, Sung TY, Wu YW, Chen YY, et al The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells. Clin Epigenetics. 2018;10(1):162. Doi: https://doi.org/10.1186/s13148-018-0595-8. ID - ref46 ER - TY - JOUR AU - Lee, T. B. AU - Moon, Y. S. AU - Choi, C. H. PY - 2012 DA - 2012// TI - Histone H4 deacetylation down-regulates catalase gene expression in doxorubicin-resistant AML subline JO - Cell Biol Toxicol. VL - 28 UR - https://doi.org/10.1007/s10565-011-9201-y DO - 10.1007/s10565-011-9201-y ID - Lee2012 ER - TY - JOUR AU - Yan, B. AU - Chen, Q. AU - Shimada, K. AU - Tang, M. AU - Li, H. AU - Gurumurthy, A. PY - 2019 DA - 2019// TI - Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia JO - Leukemia VL - 33 UR - https://doi.org/10.1038/s41375-018-0279-6 DO - 10.1038/s41375-018-0279-6 ID - Yan2019 ER - TY - JOUR AU - Viré, E. AU - Brenner, C. AU - Deplus, R. AU - Blanchon, L. AU - Fraga, M. AU - Didelot, C. PY - 2006 DA - 2006// TI - The Polycomb group protein EZH2 directly controls DNA methylation JO - Nature VL - 439 UR - https://doi.org/10.1038/nature04431 DO - 10.1038/nature04431 ID - Viré2006 ER - TY - JOUR AU - Romanchikova, N. AU - Trapencieris, P. PY - 2019 DA - 2019// TI - Wedelolactone Targets EZH2-mediated histone H3K27 methylation in mantle cell lymphoma JO - Anticancer Res. VL - 39 UR - https://doi.org/10.21873/anticanres.13577 DO - 10.21873/anticanres.13577 ID - Romanchikova2019 ER - TY - JOUR AU - Ueda, K. AU - Yoshimi, A. AU - Kagoya, Y. AU - Nishikawa, S. AU - Marquez, V. E. AU - Nakagawa, M. PY - 2014 DA - 2014// TI - Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16 JO - Cancer Sci. VL - 105 UR - https://doi.org/10.1111/cas.12386 DO - 10.1111/cas.12386 ID - Ueda2014 ER - TY - JOUR AU - Ma, L. AU - Zhang, X. AU - Wang, Z. AU - Huang, L. AU - Meng, F. AU - Hu, L. PY - 2019 DA - 2019// TI - Anti-cancer effects of curcumin on myelodysplastic syndrome through the inhibition of enhancer of zeste homolog-2 (EZH2) JO - Curr Cancer Drug Targets. VL - 19 UR - https://doi.org/10.2174/1568009619666190212121735 DO - 10.2174/1568009619666190212121735 ID - Ma2019 ER - TY - JOUR AU - Ning, X. AU - Shi, Z. AU - Liu, X. AU - Zhang, A. AU - Han, L. AU - Jiang, K. PY - 2015 DA - 2015// TI - DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression JO - Cancer Lett. VL - 359 UR - https://doi.org/10.1016/j.canlet.2015.01.005 DO - 10.1016/j.canlet.2015.01.005 ID - Ning2015 ER - TY - JOUR AU - Momparler, R. L. AU - Idaghdour, Y. AU - Marquez, V. E. AU - Momparler, L. F. PY - 2012 DA - 2012// TI - Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation JO - Leuk Res. VL - 36 UR - https://doi.org/10.1016/j.leukres.2012.03.001 DO - 10.1016/j.leukres.2012.03.001 ID - Momparler2012 ER - TY - JOUR AU - Xu, F. AU - Guo, H. AU - Shi, M. AU - Liu, S. AU - Wei, M. AU - Sun, K. PY - 2019 DA - 2019// TI - A combination of low-dose decitabine and chidamide resulted in synergistic effects on the proliferation and apoptosis of human myeloid leukemia cell lines JO - Am J Transl Res VL - 11 ID - Xu2019 ER - TY - JOUR AU - Mao, J. AU - Li, S. AU - Zhao, H. AU - Zhu, Y. AU - Hong, M. AU - Zhu, H. PY - 2018 DA - 2018// TI - Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines JO - Am J Transl Res VL - 10 ID - Mao2018 ER - TY - JOUR AU - Fiskus, W. AU - Buckley, K. AU - Rao, R. AU - Mandawat, A. AU - Yang, Y. AU - Joshi, R. PY - 2009 DA - 2009// TI - Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells JO - Cancer Biol Ther. VL - 8 UR - https://doi.org/10.4161/cbt.8.10.8213 DO - 10.4161/cbt.8.10.8213 ID - Fiskus2009 ER - TY - JOUR AU - Fiskus, W. AU - Pranpat, M. AU - Balasis, M. AU - Herger, B. AU - Rao, R. AU - Chinnaiyan, A. PY - 2006 DA - 2006// TI - Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells JO - Mol Cancer Ther. VL - 5 UR - https://doi.org/10.1158/1535-7163 DO - 10.1158/1535-7163 ID - Fiskus2006 ER - TY - JOUR AU - Fiskus, W. AU - Wang, Y. AU - Sreekumar, A. AU - Buckley, K. M. AU - Shi, H. AU - Jillella, A. PY - 2009 DA - 2009// TI - Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells JO - Blood VL - 114 UR - https://doi.org/10.1182/blood-2009-03-213496 DO - 10.1182/blood-2009-03-213496 ID - Fiskus2009 ER - TY - JOUR AU - Romanelli, A. AU - Stazi, G. AU - Fioravanti, R. AU - Zwergel, C. AU - Bello, E. AU - Pomella, S. PY - 2020 DA - 2020// TI - Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells JO - ACS Med Chem Lett. VL - 11 UR - https://doi.org/10.1021/acsmedchemlett.0c00014 DO - 10.1021/acsmedchemlett.0c00014 ID - Romanelli2020 ER - TY - JOUR AU - Cortes, J. E. AU - Gutzmer, R. AU - Kieran, M. W. AU - Solomon, J. A. PY - 2019 DA - 2019// TI - Hedgehog signaling inhibitors in solid and hematological cancers JO - Cancer Treat Rev. VL - 76 UR - https://doi.org/10.1016/j.ctrv.2019.04.005 DO - 10.1016/j.ctrv.2019.04.005 ID - Cortes2019 ER - TY - JOUR AU - Zhao, C. AU - Chen, A. AU - Jamieson, C. H. AU - Fereshteh, M. AU - Abrahamsson, A. AU - Blum, J. PY - 2009 DA - 2009// TI - Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia JO - Nature VL - 458 UR - https://doi.org/10.1038/nature07737 DO - 10.1038/nature07737 ID - Zhao2009 ER - TY - JOUR AU - Queiroz, K. C. AU - Ruela-de-Sousa, R. R. AU - Fuhler, G. M. AU - Aberson, H. L. AU - Ferreira, C. V. AU - Peppelenbosch, M. P. PY - 2010 DA - 2010// TI - Hedgehog signaling maintains chemoresistance in myeloid leukemic cells JO - Oncogene VL - 29 UR - https://doi.org/10.1038/onc.2010.375 DO - 10.1038/onc.2010.375 ID - Queiroz2010 ER - TY - JOUR AU - Kong, Y. AU - Peng, Y. AU - Liu, Y. AU - Xin, H. AU - Zhan, X. AU - Tan, W. PY - 2015 DA - 2015// TI - Twist1 and Snail link Hedgehog signaling to tumor-initiating cell-like properties and acquired chemoresistance independently of ABC transporters JO - Stem Cells. VL - 33 UR - https://doi.org/10.1002/stem.1955 DO - 10.1002/stem.1955 ID - Kong2015 ER - TY - JOUR AU - Fukushima, N. AU - Minami, Y. AU - Kakiuchi, S. AU - Kuwatsuka, Y. AU - Hayakawa, F. AU - Jamieson, C. PY - 2016 DA - 2016// TI - Small-molecule hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells JO - Cancer Sci. VL - 107 UR - https://doi.org/10.1111/cas.13019 DO - 10.1111/cas.13019 ID - Fukushima2016 ER - TY - JOUR AU - Kobune, M. AU - Takimoto, R. AU - Murase, K. AU - Iyama, S. AU - Sato, T. AU - Kikuchi, S. PY - 2009 DA - 2009// TI - Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells JO - Cancer Sci. VL - 100 UR - https://doi.org/10.1111/j.1349-7006.2009.01111.x DO - 10.1111/j.1349-7006.2009.01111.x ID - Kobune2009 ER - TY - JOUR AU - Long, B. AU - Wang, L. X. AU - Zheng, F. M. AU - Lai, S. P. AU - Xu, D. R. AU - Hu, Y. PY - 2016 DA - 2016// TI - Targeting GLI1 suppresses cell growth and enhances chemosensitivity in CD34+ enriched acute myeloid leukemia progenitor cells JO - Cell. Physiol. Biochem. VL - 38 UR - https://doi.org/10.1159/000443075 DO - 10.1159/000443075 ID - Long2016 ER - TY - JOUR AU - Lin, S. AU - Shaik, N. AU - Chan, G. AU - Cortes, J. E. AU - Ruiz-Garcia, A. PY - 2020 DA - 2020// TI - An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure JO - Cancer Chemother Pharmacol. VL - 86 UR - https://doi.org/10.1007/s00280-020-04132-x DO - 10.1007/s00280-020-04132-x ID - Lin2020 ER - TY - JOUR AU - Cortes, J. E. AU - Douglas Smith, B. AU - Wang, E. S. AU - Merchant, A. AU - Oehler, V. G. AU - Arellano, M. PY - 2018 DA - 2018// TI - Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results JO - Am J Hematol. VL - 93 UR - https://doi.org/10.1002/ajh.25238 DO - 10.1002/ajh.25238 ID - Cortes2018 ER - TY - JOUR AU - Cortes, J. E. AU - Heidel, F. H. AU - Fiedler, W. AU - Smith, B. D. AU - Robak, T. AU - Montesinos, P. PY - 2020 DA - 2020// TI - Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy JO - J Hematol Oncol. VL - 13 UR - https://doi.org/10.1186/s13045-020-00929-8 DO - 10.1186/s13045-020-00929-8 ID - Cortes2020 ER - TY - JOUR AU - Chaudhry, P. AU - Singh, M. AU - Triche, T. J. AU - Guzman, M. AU - Merchant, A. A. PY - 2017 DA - 2017// TI - GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML JO - Blood VL - 129 UR - https://doi.org/10.1182/blood-2016-05-718585 DO - 10.1182/blood-2016-05-718585 ID - Chaudhry2017 ER - TY - JOUR AU - Gruber, W. AU - Peer, E. AU - Elmer, D. P. AU - Sternberg, C. AU - Tesanovic, S. AU - Burgo, P. PY - 2018 DA - 2018// TI - Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance JO - Int J Cancer. VL - 142 UR - https://doi.org/10.1002/ijc.31117 DO - 10.1002/ijc.31117 ID - Gruber2018 ER - TY - JOUR AU - Fan, C. W. AU - Yarravarapu, N. AU - Shi, H. AU - Kulak, O. AU - Kim, J. AU - Chen, C. PY - 2018 DA - 2018// TI - A synthetic combinatorial approach to disabling deviant Hedgehog signaling JO - Sci Rep. VL - 8 UR - https://doi.org/10.1038/s41598-018-19408-9 DO - 10.1038/s41598-018-19408-9 ID - Fan2018 ER - TY - JOUR AU - Chun, S. G. AU - Park, H. AU - Pandita, R. K. AU - Horikoshi, N. AU - Pandita, T. K. AU - Schwartz, D. L. PY - 2015 DA - 2015// TI - Targeted inhibition of histone deacetylases and hedgehog signaling suppress tumor growth and homologous recombination in aerodigestive cancers JO - Am J Cancer Res VL - 5 ID - Chun2015 ER - TY - JOUR AU - Zhao, J. AU - Quan, H. AU - Xie, C. AU - Lou, L. PY - 2014 DA - 2014// TI - NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations JO - Pharmacol Res Perspect. VL - 2 UR - https://doi.org/10.1002/prp2.43 DO - 10.1002/prp2.43 ID - Zhao2014 ER -